Key barriers remain: defining tumor-specific TLR4 signaling thresholds (e.g., distinguishing CRC’s pro-metastatic vs. radiotherapy’s anti-tumor effects), optimizing targeted delivery, and addressing confounders like gut dysbiosis (which modulates systemic LPS levels). This evidence concerns the gene TLR4 and colorectal carcinoma.